Compare Novo Nordisk A/S (NVO) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Valero Energy Corporation — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while Valero Energy Corporation trades at $443.43 (market cap $127.78B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Valero Energy Corporation for 56 Days on average.
| NVO | VLO | |
|---|---|---|
Market Cap | $165.31B | $127.78B |
Volume | 11,432,838 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $63.98 | $443.80 |
52-Week Low | $35.29 | $156.39 |
Typical Hold Time | 116 Days | 56 Days |
Enterprise Value | $179.56B | $131.26B |
Dividend Yield | 4.71% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Valero Energy (VLO) trades at $441.93, up 4.2% today, near its 52-week high with strong bullish momentum from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%, supported by a robust ROE of 29.31%. Analyst consensus is bullish with a $408.10 price target, though RSI levels indicate overbought conditions.
VLO's outlook is positive due to refining margin strength and earnings beats, but risks include volatile energy prices and potential policy impacts like diesel export bans. The stock offers growth potential with a reasonable P/E of 18.51, yet high valuation multiples and technical overbought signals warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
